H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $80 from $70 and keeps a Buy rating on the shares. The firm now includes BBP-418 in its valuation assessment with an 80% probability of approval. BridgeBio reported “highly favorable and clinically meaningful” top-line interim data from the Phase 3 FORTIFY trial of BBP-418 in patients with limb girdle muscular dystrophy, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Announces Positive Phase 3 Study Results
- BridgeBio Pharma’s Promising Phase 3 Results and Accelerated Approval Path Justify Buy Rating
- BridgeBio price target raised to $69 from $59 at Raymond James
- Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations
- BridgeBio reports results from FORTIFY Phase 3 study of BBP-418